Leukotriene E4, Random
| Label Mnemonic: | LTE4 |
| Epic code: | LAB8635 |
| Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
6240-8 RCP
356-8593
Collect 5mL random urine specimen in a labeled sterile urine cup. Transfer to a labelled yellow top urine tube (no additive) and send to the laboratory.
Random collection
Preferred Minimum: 5 mL urine
Absolute Minimum: 3 mL urine
2 to 9 days upon receipt at reference laboratory.
< or =104 pg/mg creatinine
Elevated urinary leukotriene E4 (LTE4) concentrations >104 pg/mg creatinine are consistent with the diagnosis of systemic mast cell disease when combined with clinical signs and symptoms. Pharmacological treatment with 5-lipoxygenase inhibitors or leukotriene receptor antagonists has been shown to decrease production of LTE4.
Urinary LTE4 may be used together with serum tryptase, urinary 2,3-dinor 11 beta-prostaglandin F2 alpha, and/or urinary N-methyl histamine.
LTE4: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
AACT: Enzymatic Colorimetric Assay
Urine Tests Requiring Preservatives, Refrigeration or Special Containers
Urine Tests Requiring no Preservatives


Useful as an aid to evaluate patients suspected of having systemic mastocytosis.
When leukotriene E4 testing is performed, urine creatinine will always be performed at no additional charge.
Cautions:
Patients taking 5-lipoxygenase inhibitor Zileuton/Zyflo may have decreased concentrations of leukotriene E4 (LTE4) if dosage has not been discontinued for 48 hours.
Systemic mastocytosis is a heterogenous disease and lack of elevated LTE4 does not exclude the diagnosis of mast cell disease.
Increased excretion of LTE4 has also been reported in the following conditions: asthma, eosinophilic pneumonia, respiratory syncytial virus infection, atopic dermatitis, Crohn disease, and rheumatoid arthritis.
This assay measures both LTE4 and the 11-trans-LTE4 as markers of mast cell release.